A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.

@article{Corya2006A2O,
  title={A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.},
  author={S. Corya and R. Perlis and P. Keck and D. Lin and M. Case and D. Williamson and M. Tohen},
  journal={The Journal of clinical psychiatry},
  year={2006},
  volume={67 5},
  pages={
          798-806
        }
}
OBJECTIVE Olanzapine-fluoxetine combination has shown efficacy in the acute treatment of depressive episodes in patients with bipolar I disorder. The present analyses examined the efficacy and safety of longer term treatment with olanzapine-fluoxetine combination or olanzapine monotherapy in a 6-month open-label extension study. METHOD 376 patients with DSM-IV bipolar I disorder, depressed, who completed an acute trial entered the open-label study and received 1 week of olanzapine monotherapy… Expand
Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.
Olanzapine/Fluoxetine
Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression
  • S. Dubovsky
  • Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2013
Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility
  • S. Dodd, M. Berk
  • Psychology, Medicine
  • Expert review of neurotherapeutics
  • 2008
Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis
...
1
2
3
4
5
...